• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

coronavirus

BD is playing a crucial role delivering COVID-19 vaccines: Here’s how

December 15, 2020 By Chris Newmarker

BD needles syringes

Hundreds of millions of vaccine doses will require hundreds of millions of syringes from companies such as BD. As much-hoped-for COVID-19 vaccines roll out to the public, Becton Dickinson (NYSE:BDX) faces an arguably impressive challenge: The Franklin Lakes, N.J.–based medtech giant already has commitments to provide more than 800 million needles and syringes to deliver future COVID-19 […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: BD, coronavirus, COVID-19, syringes

HHS gives Vaxxas $22M to support vaccine patch tech

October 5, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup Tagged With: BARDA, coronavirus, COVID-19, HHS, Merck, Vaxxas

Ampio gains investigational drug nod for COVID-19 inhaler

September 28, 2020 By Danielle Kirsh

ampio

Ampio recently announced that it received FDA investigational new drug designation to proceed with clinical trials of its Ampion inhaler for patients with COVID-19 respiratory distress. The company is expanding on its recent successful Phase I trial that administered the drug intravenously to COVID-19 patients. The new Phase I trial of inhaled Ampion will total […]

Filed Under: Pharmaceuticals Tagged With: Ampio Pharmaceutical, coronavirus, COVID-19

Report: China begins testing COVID-19 nasal spray vaccine

September 11, 2020 By Sean Whooley

coronavirus COVID-19

China has reportedly begun human testing for a COVID-19 vaccine which utilizes nasal spray instead of an injection. A report in Bloomberg cites a registration in the Chinese Clinical Trial Registry confirming that the nasal spray vaccine candidate developed by Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise is undergoing Phase I human testing. Get the […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19

Thermo Fisher to manufacture Inovio COVID-19 vaccine candidate

September 9, 2020 By Sean Whooley

Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by […]

Filed Under: Business/Financial News, Clinical Trials, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, thermofisherscientific

Could Vaxxas’ tiny patches enable a better COVID-19 vaccine?

September 2, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Tiny vaccine delivery patches could solve logistical challenges, but they face manufacturing hurdles. Here’s how Vaxxas is trying to overcome them. Merck (NYSE:MRK) and Vaxxas announced earlier this year that the pharmaceutical giant was using Vaxxas’ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate. Vaxxas did not disclose what […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Harro Höfliger, Merck, Vaxxas

CureVac stock soars after $213.3M IPO

August 17, 2020 By Sean Whooley

Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: coronavirus, COVID-19, CureVac

PerkinElmer launches high-volume COVID-19 test workstations

August 17, 2020 By Sean Whooley

PerkinElmer

PerkinElmer (NYSE:PKI) announced today that it launched a series of Explorer workstations for increasing COVID-19 testing capabilities. Waltham, Mass.-based PerkinElmer touts its Explorer workstations as capable of preparing and running up to 10,000 COVID-19 tests per day, enabling laboratories to ramp up their testing for the SARS-CoV-2 virus causing coronavirus and generate quick results. According to […]

Filed Under: Business/Financial News, Diagnostics, Featured Tagged With: coronavirus, COVID-19, perkinelmer

Report: Will Dr. Hahn crack under political pressure?

August 10, 2020 By Nancy Crotti

Many jobs have come with increased stress levels during the coronavirus pandemic, from ICU staff to Walmart greeters. Now officials who’ve been keeping tabs on FDA commissioner Dr. Stephen Hahn are wondering whether he can weather the strain of defending science while working for the Trump administration. Hahn has been squeezed between expressing his professional […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Centers for Disease Control & Prevention, coronavirus, COVID-19, Donald Trump, FDA, U.S. Department of Health & Human Services

Insulet up on Street-beating Q2, raised guidance

August 7, 2020 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast. The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: coronavirus, COVID-19, Insulet

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS